相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells
Linda Quatrini et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2021)
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Deborah Blythe Doroshow et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Interaction Between MDSC and NK Cells in Solid and Hematological Malignancies: Impact on HSCT
Nicola Tumino et al.
FRONTIERS IN IMMUNOLOGY (2021)
Impact of the corticosteroid indication and administration route on overall survival and the tumor response after immune checkpoint inhibitor initiation
Louis Gaucher et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
Interchangeability of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy
Emina Torlakovic et al.
MODERN PATHOLOGY (2020)
Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis
Guoxuan Gao et al.
BMC CANCER (2020)
PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs
Yujun Park et al.
CANCER RESEARCH AND TREATMENT (2020)
PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade
Marcel P. Trefny et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Targets and Antibody Formats for Immunotherapy of Neuroblastoma
Jeong A. Park et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Immunoscore and its introduction in clinical practice
Jerome Galon et al.
QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2020)
Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay
Hans Juergen Grote et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial
Kara L. Davis et al.
LANCET ONCOLOGY (2020)
Endogenous Glucocorticoid Signaling Regulates CD8+T Cell Differentiation and Development of Dysfunction in the Tumor Microenvironment
Nandini Acharya et al.
IMMUNITY (2020)
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies
Shogo Kumagai et al.
NATURE IMMUNOLOGY (2020)
PD-1-positive Natural Killer Cells have a weaker antitumor function than that of PD-1-negative Natural Killer Cells in Lung Cancer
Chao Niu et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2020)
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Aurelien Marabelle et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer
Karina Kulangara et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2019)
Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
O. Hamid et al.
ANNALS OF ONCOLOGY (2019)
Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor
Nicola Tumino et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
Paul Nghiem et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer: Phase III KEYNOTE-)181 study.
Takashi Kojima et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
Martin Reck et al.
LANCET RESPIRATORY MEDICINE (2019)
PD-L1 expression in non-small cell lung cancer: evaluation of the diagnostic accuracy of a laboratory-developed test using clone E1L3N in comparison with 22C3 and SP263 assays
Enrico Munari et al.
HUMAN PATHOLOGY (2019)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 Study
Hyun Cheol Chung et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of pembrolizumab (pembro) as first-line therapy for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Danny Rischin et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Tony S. K. Mok et al.
LANCET (2019)
Programmed Cell Death-1 Receptor (PD-1)-Mediated Regulation of Innate Lymphoid Cells
Grace Mallett et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study
Edward B. Garon et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Diversity, Mechanisms, and Significance of Macrophage Plasticity
Massimo Locati et al.
Annual Review of Pathology-Mechanisms of Disease (2019)
Glucocorticoids potentiate the inhibitory capacity of programmed cell death 1 by up-regulating its expression on T cells
Natsumi Maeda et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Mechanisms Controlling PD-L1 Expression in Cancer
Jong-Ho Cha et al.
MOLECULAR CELL (2019)
The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors
Andrew A. Davis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A Comprehensive Analysis of Key Immune Checkpoint Receptors on Tumor-Infiltrating T Cells From Multiple Types of Cancer
Xi Li et al.
FRONTIERS IN ONCOLOGY (2019)
Expression of programmed cell death ligand 1 in non-small cell lung cancer: Comparison between cytologic smears, core biopsies, and whole sections using the SP263 assay
Enrico Munari et al.
CANCER CYTOPATHOLOGY (2019)
Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study
J. von Pawel et al.
EUROPEAN JOURNAL OF CANCER (2019)
Immunotherapies for pediatric cancer: current landscape and future perspectives
Brian Hutzen et al.
CANCER AND METASTASIS REVIEWS (2019)
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
Martin Reck et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Avelumab in patients with previously treated metastatic melanoma: phase 1b results from the JAVELIN Solid Tumor trial
Ulrich Keilholz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?
Sylvain Simon et al.
ONCOIMMUNOLOGY (2018)
PD-L1 Assays 22C3 and SP263 are Not Interchangeable in Non-Small Cell Lung Cancer When Considering Clinically Relevant Cutoffs An Interclone Evaluation by Differently Trained Pathologists
Enrico Munari et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2018)
Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL
Frank Vari et al.
BLOOD (2018)
Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell-rich and exhausted T-effector microenvironment
Fathima Zumla Cader et al.
BLOOD (2018)
Activated innate lymphoid cell populations accumulate in human tumour tissues
Maryam Salimi et al.
BMC CANCER (2018)
Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations
Bryce Noll et al.
CANCER CYTOPATHOLOGY (2018)
Nitric Oxide Production by Myeloid-Derived Suppressor Cells Plays a Role in Impairing Fc Receptor-Mediated Natural Killer Cell Function
Andrew Stiff et al.
CLINICAL CANCER RESEARCH (2018)
Digital Microscopy, Image Analysis, and Virtual Slide Repository
Famke Aeffner et al.
ILAR JOURNAL (2018)
PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections
Enrico Munari et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project
Ming Sound Tsao et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
M. R. Migden et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Expression of PD-1 on CD4+ Tumor-Infiltrating Lymphocytes in Tumor Microenvironment Associated with Pathological Characteristics of Breast Cancer
Yan-Jie Zhao et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2018)
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer Phase 2 Clinical KEYNOTE-059 Trial
Charles S. Fuchs et al.
JAMA ONCOLOGY (2018)
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)
Julie R. Brahmer et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Endogenous glucocorticoids control host resistance to viral infection through the tissue-specific regulation of PD-1 expression on NK cells
Linda Quatrini et al.
NATURE IMMUNOLOGY (2018)
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. J. Antonia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer
L. Paz-Ares et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
Hyung-Don Kim et al.
GASTROENTEROLOGY (2018)
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
P. Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression
Colt A. Egelston et al.
NATURE COMMUNICATIONS (2018)
Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value
Giulia Mazzaschi et al.
CLINICAL CANCER RESEARCH (2018)
Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018
Tanvir F. Kabir et al.
OCHSNER JOURNAL (2018)
Early Effector T Lymphocytes Coexpress Multiple Inhibitory Receptors in Primary Non-Small Cell Lung Cancer
Elena Tassi et al.
CANCER RESEARCH (2017)
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
Guoying Zhou et al.
GASTROENTEROLOGY (2017)
Efficacy and safety of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma (rrPMBCL): interim analysis of the KEYNOTE-170 phase 2 trial
P. Zinzani et al.
HEMATOLOGICAL ONCOLOGY (2017)
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma
Robert Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immune checkpoints on innate lymphoid cells
Laura Chiossone et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project
Fred R. Hirsch et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review
Robert Brody et al.
LUNG CANCER (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
J. Weber et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers
Y. Liu et al.
ONCOGENE (2017)
Targeting the PD-1 pathway in pediatric solid tumors and brain tumors
Lars M. Wagner et al.
ONCOTARGETS AND THERAPY (2017)
A molecular portrait of microsatellite instability across multiple cancers
Isidro Cortes-Ciriano et al.
NATURE COMMUNICATIONS (2017)
PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability
Enrico Munari et al.
ONCOTARGET (2017)
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer
David L. Rimm et al.
JAMA ONCOLOGY (2017)
Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study
A. Necchi et al.
ANNALS OF ONCOLOGY (2017)
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer
Wendy A. Cooper et al.
CLINICAL CANCER RESEARCH (2017)
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer
Marianne J. Ratcliffe et al.
CLINICAL CANCER RESEARCH (2017)
PD-L1 expression in metastatic neuroblastoma as an additional mechanism for limiting immune surveillance
Alessandra Dondero et al.
ONCOIMMUNOLOGY (2016)
Programmed Death Ligand-1 Immunohistochemistry Friend or Foe?
Keith M. Kerr et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
T-cell defect in diffuse large B-cell lymphomas involves expansion of myeloid-derived suppressor cells
Imane Azzaoui et al.
BLOOD (2016)
Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set
Jason Roszik et al.
BMC MEDICINE (2016)
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer
Elisabeth Brambilla et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
Louis Fehrenbacher et al.
LANCET (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study
Corey J. Langer et al.
LANCET ONCOLOGY (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
A. M. M. Eggermont et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade
Valerie Lee et al.
ONCOLOGIST (2016)
Expression of immune checkpoints in T cells of esophageal cancer patients
Xie Jinhua et al.
ONCOTARGET (2016)
PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma
Asma Beldi-Ferchiou et al.
ONCOTARGET (2016)
The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells
Chunwan Lu et al.
ONCOIMMUNOLOGY (2016)
PD-L1+ MDSCs are increased in HCC patients and induced by soluble factor in the tumor microenvironment
Tomoaki Iwata et al.
SCIENTIFIC REPORTS (2016)
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer
Ryan Montler et al.
CLINICAL & TRANSLATIONAL IMMUNOLOGY (2016)
Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy
Kailin Xing et al.
BMC IMMUNOLOGY (2015)
The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
Kathleen M. Mahoney et al.
CLINICAL THERAPEUTICS (2015)
Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art?
Keith M. Kerr et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
Antoni Ribas et al.
LANCET ONCOLOGY (2015)
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
Jeffrey S. Weber et al.
LANCET ONCOLOGY (2015)
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy
Ferdousi Chowdhury et al.
ONCOIMMUNOLOGY (2015)
Biochemical Signaling of PD-1 on T Cells and Its Functional Implications
Vassiliki A. Boussiotis et al.
CANCER JOURNAL (2014)
PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Alena Gros et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Towards the introduction of the 'Immunoscore' in the classification of malignant tumours
Jerome Galon et al.
JOURNAL OF PATHOLOGY (2014)
Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
Caroline Robert et al.
LANCET (2014)
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Roy S. Herbst et al.
NATURE (2014)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
Alexander W. MacFarlane et al.
CANCER IMMUNOLOGY RESEARCH (2014)
High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells
June H. Myklebust et al.
BLOOD (2013)
Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study
Nancy E. Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Programmed Death Ligand 1 Is Expressed by Non-Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells
David J. Andorsky et al.
CLINICAL CANCER RESEARCH (2011)
Progressive Upregulation of PD-1 in Primary and Metastatic Melanomas Associated with Blunted TCR Signaling in Infiltrating T Lymphocytes
Maxime Chapon et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
B7-H1 is correlated with malignancy-grade gliomas but is not expressed exclusively on tumor stem-like cells
Yu Yao et al.
NEURO-ONCOLOGY (2009)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
Clinical significance of B7-H1 (PD-L1) expression in human acute leukemia
Xiangli Chen et al.
CANCER BIOLOGY & THERAPY (2008)
Tissue expression of PD-L1 mediates peripheral T cell tolerance
ME Keir et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)